Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Financings Of The Fortnight: Idenix To Forge Ahead On HCV Combo After Novartis’ Departure

Aug 10 2012

• By Amanda Micklus and Maureen Riordan

Related Content

Does Bristol Nuc’s Possible Cardiac Toxicity Portend A Class Effect?

Aug 06 2012

Related Companies

Idenix Pharmaceuticals, Inc.

Novartis AG

Gilead Sciences, Inc.

Bristol Myers Squibb Company

Inhibitex, Inc.

Vertex Pharmaceuticals Incorporated

Endo, Inc.

Mersana Therapeutics, Inc.

Hyperion Therapeutics, Inc.

Bausch Health Companies Inc.

AGC Biologics SPA

Aegerion Pharmaceuticals, Inc.

Novagali Pharma SA

Santen Pharmaceutical Co., Ltd.

Millendo Therapeutics, Inc.

Roche Holding AG

Astellas Pharma, Inc.

Astellas Pharma, Inc.

Exelixis, Inc.

GSK plc

Sanofi

Additional Topics

Business Strategies BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window